What is Regeneron?
Regeneron is a biotechnology medicines company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Biotechnology medicines
- Headquarters
- Tarrytown, NY
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: REGN
What is Regeneron?
Regeneron is a biotechnology medicines company headquartered in Tarrytown, NY. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Regeneron is a biotechnology medicines company headquartered in Tarrytown, NY. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Regeneron should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Regeneron offer?
Regeneron's profile centers on EYLEA, Dupixent collaboration, Immunology, Oncology.
- EYLEA· Biotechnology medicines
- Dupixent collaboration· Biotechnology medicines
- Immunology· Biotechnology medicines
- Oncology· Biotechnology medicines
- Genetics platform· Biotechnology medicines
- Clinical pipeline· Biotechnology medicines
How does Regeneron make money?
Regeneron makes money through commercial activity tied to biotechnology medicines.
Regeneron monetizes through the model common to biotechnology medicines: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Regeneron?
Regeneron's named executives should be verified on the official leadership or investor-relations page before outreach.
- Regeneron executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Regeneron finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Regeneron operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Regeneron's leadership?
Regeneron should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.regeneron.com- Regeneron investor relationsInvestor relations / corporate contactcontact via https://www.regeneron.com
How is Regeneron funded?
Regeneron's current status is Public company; Nasdaq: REGN.
Regeneron's capital profile is best understood through its current public-company status: Public company; Nasdaq: REGN. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Regeneron get here?
Regeneron's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingRegeneron is foundedThe company begins building in biotechnology medicines.
- Scale-upCommercial footprint expandsRegeneron broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: REGNPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Regeneron's competitors?
Regeneron competes with larger incumbents and focused specialists in biotechnology medicines.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Regeneron — frequently asked questions
